'CMC Contrast AB (Copenhagen Malmø Contrast AB) was established in April 2000. CMC Contrast AB was founded by professor Henrik Thomsen and the two main owners Malmøhus Invest AB and Öresund - Healthcare Capital KS.'
'The purpose of CMC Contrast AB is to develop the product CMC 001 to a registered medicinal product with market authorisation in the international pharmaceutical markets. CMC Contrast AB holds all the rights to CMC 001, and the company aims to develop CMC 001 to a registered medicinal product on a worldwide basis.'

Short name: CMC 001, central moiety: Mn2+
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract. Applications are screening of liver tumors/metastases, imaging of the biliary tract and it could be suitable for liver function studies by following the metabolism and excretion of manganese in the liver cells. Several advantages like better images, higher safety, lower costs and less inconvenience for the patient can be expected.
Animal experiments and clinical studies in humans Phase I and Phase II A, have shown excellent contrast enhancing properties with only minimal adverse effects. CMC 001 is under development by the Medicon Valley based CMC Contrast AB to receive a cost effective, safe and highly diagnostic MR contrast medium for abdominal MR imaging. Clinical studies in Phase III are started.